BRIEF-Sanofi and Regeneron accepted for priority review by U.S. FDA

* Sanofi and Regeneron announce dupilumab biologics license application accepted for priority review by U.S. FDA Source text for Eikon: Further company coverage: (Gdynia Newsroom)